Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT01335477
Registration number
NCT01335477
Ethics application status
Date submitted
13/04/2011
Date registered
14/04/2011
Date last updated
25/07/2016
Titles & IDs
Public title
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients II
Query!
Scientific title
A 52 Weeks, Double Blind, Randomized, Placebo-controlled Trial Evaluating the Effect of Oral BIBF 1120, 150 mg Twice Daily, on Annual Forced Vital Capacity Decline, in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Query!
Secondary ID [1]
0
0
2010-024252-29
Query!
Secondary ID [2]
0
0
1199.34
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Pulmonary Fibrosis
0
0
Query!
Advanced Cancer
0
0
Query!
Condition category
Condition code
Respiratory
0
0
0
0
Query!
Other respiratory disorders / diseases
Query!
Inflammatory and Immune System
0
0
0
0
Query!
Connective tissue diseases
Query!
Inflammatory and Immune System
0
0
0
0
Query!
Other inflammatory or immune system disorders
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - placebo
Treatment: Drugs - BIBF 1120
Placebo comparator: placebo - patient receives capsules identical to those containing active drug
Experimental: BIBF 1120 - patient receives capsules containing BIBF 1120 twice a day
Experimental: Non-comparative, open-label Nabiximols - Nabiximols was self-administered by participants as a 100 microliter (µL) oromucosal spray, in the morning and evening, up to a maximum of 10 sprays per day for 6 months. Nabiximols oromucosal spray contained delta-9-tetrahydrocannabinol (THC) (27 milligrams \[mg\]/milliliter \[mL\]):cannabidiol (CBD) (25 mg/mL), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavoring. Each 100 µL actuation delivered 2.7 mg THC and 2.5 mg CBD.
Treatment: Drugs: placebo
placebo matching BIBF 1120 BID
Treatment: Drugs: BIBF 1120
BIBF 1120 BID (twice daily)
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Annual Rate of Decline in Forced Vital Capacity (FVC) Over 52 Weeks.
Query!
Assessment method [1]
0
0
Forced vital capacity (FVC) is the total amount of air exhaled during the lung function test.
For this endpoint reported means represent the adjusted rate.
Query!
Timepoint [1]
0
0
52 weeks
Query!
Primary outcome [2]
0
0
Percent Of Participants With Treatment-emergent Adverse Events
Query!
Assessment method [2]
0
0
Treatment-emergent Adverse Events (TEAEs) were coded according to the Medical Dictionary for Regulatory Activities (MedDRA) dictionary version 17.0. A TEAE is defined as an adverse event with an onset after the start of study drug treatment. The percent of participants who experienced one or more TEAEs is reported.
Query!
Timepoint [2]
0
0
Baseline, Day 183
Query!
Secondary outcome [1]
0
0
Change From Baseline in Saint George's Respiratory Questionnaire (SGRQ) Total Score at 52 Weeks
Query!
Assessment method [1]
0
0
This is a key secondary endpoint. SGRQ is a health-related quality of life questionnaire divided into 3 components : symptoms, activity and impact.
The total score (summed weights) can range from 0 to 100 with a lower score denoting a better health status.
Means provided are the adjusted means based on all analyzed patients in the model (not only patients with a baseline and measurement at week 52).
Query!
Timepoint [1]
0
0
Baseline and 52 weeks
Query!
Secondary outcome [2]
0
0
Time to First Acute Idiopathic Pulmonary Fibrosis (IPF) Exacerbation
Query!
Assessment method [2]
0
0
Due to rare events, the median of time to event is not calculable, thus the percentages of patients with (IPF) exacerbation are reported and represented as a key secondary endpoint. An acute exacerbation (reported as an AE by the investigator) was defined as follows:
Otherwise unexplained clinical features including all of the following:
Unexplained worsening or development of dyspnoea within 30 days New diffuse pulmonary infiltrates on chest X-ray, and/or new HRCT parenchymal abnormalities with no pneumothorax or pleural effusion (new ground-glass opacities) since the last visit Exclusion of infection as per routine clinical practice and microbiological studies Exclusion of alternative causes as per routine clinical practice including left heart failure, pulmonary embolism and identifiable cause of acute lung injury.
Failure is the proportion of patients with at least one acute IPF exacerbation over 52 weeks, based on all investigator-reported AEs .
Query!
Timepoint [2]
0
0
52 weeks
Query!
Secondary outcome [3]
0
0
Absolute Change From Baseline in Forced Vital Capacity (FVC) Over 52 Weeks
Query!
Assessment method [3]
0
0
Means provided are the adjusted means and are based on all analysed patients in the model (not only patients with a change from baseline to week 52).
Query!
Timepoint [3]
0
0
Baseline and 52 weeks
Query!
Secondary outcome [4]
0
0
Relative Change From Baseline in Forced Vital Capacity (FVC) Over 52 Weeks
Query!
Assessment method [4]
0
0
Percentage change from baseline in FVC over 52 weeks. Means provided are the adjusted means and are based on all analysed patients in the model (not only patients with a change from baseline to week 52).
Query!
Timepoint [4]
0
0
Baseline and 52 weeks
Query!
Secondary outcome [5]
0
0
Absolute Change From Baseline in Forced Vital Capacity (FVC) (% Predicted) Over 52 Weeks
Query!
Assessment method [5]
0
0
Means provided are the adjusted means and are based on all analysed patients in the model (not only patients with a change from baseline to week 52).
Query!
Timepoint [5]
0
0
Baseline and 52 weeks
Query!
Secondary outcome [6]
0
0
Relative Change From Baseline in Forced Vital Capacity (FVC) (% Predicted) Over 52 Weeks
Query!
Assessment method [6]
0
0
Percentage change from baseline in FVC (% predicted) at 52 weeks. Means provided are the adjusted means and are based on all analysed patients in the model (not only patients with a change from baseline to week 52).
Query!
Timepoint [6]
0
0
Baseline and 52 weeks
Query!
Secondary outcome [7]
0
0
Absolute Categorical Change From Baseline of FVC (% Predicted) by Categories Over 52 Weeks - 5% Threshold
Query!
Assessment method [7]
0
0
Absolute categorical change of FVC (% predicted) by categories over 52 weeks - 5% threshold (decrease by \>5%, increase by \>5%, and change within =5%).
Query!
Timepoint [7]
0
0
Baseline and 52 weeks
Query!
Secondary outcome [8]
0
0
Absolute Categorical Change From Baseline of FVC (% Predicted) by Categories Over 52 Weeks - 10% Threshold
Query!
Assessment method [8]
0
0
Absolute categorical change of FVC (% predicted) by categories over 52 weeks - 10% threshold (decrease by 10%, increase by \>10%, and change within =10%)
Query!
Timepoint [8]
0
0
Baseline and 52 weeks
Query!
Secondary outcome [9]
0
0
FVC Responders Using 10% Threshold at 52 Weeks
Query!
Assessment method [9]
0
0
FVC responders using 10% threshold at 52 weeks, defined as patients with absolute decline in FVC% predicted no greater than 10% and with an FVC evaluation at 52 weeks.
Query!
Timepoint [9]
0
0
52 weeks
Query!
Secondary outcome [10]
0
0
Proportion of FVC Responders Using 5% Threshold at 52 Weeks
Query!
Assessment method [10]
0
0
Proportion of FVC responders using 5% threshold at 52 weeks, defined as patients with absolute decline in FVC% predicted no greater than 5% and with an FVC evaluation at 52 weeks.
Query!
Timepoint [10]
0
0
52 weeks
Query!
Secondary outcome [11]
0
0
Proportion of SGRQ Responders at 52 Weeks: Patient Reported Outcomes (PROs)
Query!
Assessment method [11]
0
0
Proportion of SGRQ responders at 52 weeks.
Responders defined as \<= -4 points change in change from baseline in SGRQ total score at 52 weeks.
Query!
Timepoint [11]
0
0
baseline and 52 weeks
Query!
Secondary outcome [12]
0
0
Change From Baseline in SGRQ Symptom Score at 52 Weeks (Points): Patient Reported Outcomes (PROs)
Query!
Assessment method [12]
0
0
SGRQ Symptom score is a sub-component of SGRQ total score and is concerned with the effect of respiratory symptoms, their frequency and severity. This score calculated as summed weights ranges from 0 to 100 with lower score denoting a better symptom-related quality of life.
Means presented are the adjusted means and are based on all analyzed patients in the model (not only patients with a baseline and measurement at week 52).
Query!
Timepoint [12]
0
0
baseline and 52 weeks
Query!
Secondary outcome [13]
0
0
Change From Baseline in SGRQ Impact Score at 52 Weeks (Points): Patient Reported Outcomes (PROs)
Query!
Assessment method [13]
0
0
SGRQ Impact score is a sub-component of SGRQ total score and covers a range of aspects concerned with social functioning and psychological disturbances resulting from airway disease. This score calculated as summed weights ranges from 0 to 100 with lower score denoting a better impact-related quality of life.
Means presented are the adjusted means and are based on all analyzed patients in the model (not only patients with a baseline and measurement at week 52).
Query!
Timepoint [13]
0
0
baseline and 52 weeks
Query!
Secondary outcome [14]
0
0
Change From Baseline in SGRQ Activity Score at 52 Weeks (Points): Patient Reported Outcomes (PROs)
Query!
Assessment method [14]
0
0
SGRQ Activity score is a sub-component of SGRQ total score and concerned with activities that cause or are limited by breathlessness. This score calculated as summed weights ranges from 0 to 100 with lower score denoting a better activity-related quality of life.
Means presented are the adjusted means and are based on all analyzed patients in the model (not only patients with a baseline and measurement at week 52).
Query!
Timepoint [14]
0
0
baseline and 52 weeks
Query!
Secondary outcome [15]
0
0
Change From Baseline in Idiopathic Pulmonary Fibrosis (IPF) Specific Version of SGRQ (SGRQ-I) Total Score at 52 Weeks (Points): Patient Reported Outcomes (PROs)
Query!
Assessment method [15]
0
0
SGRQ-I is the IPF specific version of SGRQ comprises of selected items from the SGRQ divided into three components, Symptoms, Activity and Impact. Each component is scored separately. The weights for all items with a positive responses are summed and the weights from missed items are deducted from the maximum possible weight for the total score.
The total score is calculated by dividing the summed weights from positive items in the questionnaire by maximum possible weight for all items in the questionnaire. The total score can range from 0 to 100 with a lower score denoting a better health-related quality of life. Change from baseline is calculated as the difference between total score at week 52 and total score at baseline as measured by the scale.
Query!
Timepoint [15]
0
0
baseline and 52 weeks
Query!
Secondary outcome [16]
0
0
Change From Baseline in Shortness of Breath Questionnaire (SOBQ) at 52 Weeks: Patient Reported Outcomes (PROs)
Query!
Assessment method [16]
0
0
Shortness of Breath Questionnaire measures the shortness of breath. It comprises of 24 items. Each item is scored on a scale between 0-5 where 5 represents maximal breathlessness. The responses to all items are summed up to provide the overall score that can range from 0 (best outcome) to 120 (worst outcome).
Means presented are the adjusted means and are based on all analyzed patients in the model (not only patients with a baseline and measurement at week 52).
Query!
Timepoint [16]
0
0
baseline and 52 weeks
Query!
Secondary outcome [17]
0
0
Change From Baseline in Cough Symptom Score of the Cough and Sputum Assessment Questionnaire (CASA-Q) Score at 52 Weeks: Patient Reported Outcomes (PROs)
Query!
Assessment method [17]
0
0
The cough domains of the Cough and Sputum Assessment Questionnaire (CASAQ(CD)) assess the frequency and severity of cough and sputum and their impact on everyday life. It contains 4 domains cough/sputum symptom and impact with each scale ranging from 0 to 100 with lower scores indicating higher symptoms/impact levels (worst outcome).
Means presented are the adjusted means and are based on all analyzed patients in the model (not only patients with a baseline and measurement at week 52).
Query!
Timepoint [17]
0
0
baseline and 52 weeks
Query!
Secondary outcome [18]
0
0
Change From Baseline in Cough Impact Score of the Cough and Sputum Assessment Questionnaire (CASA-Q) Score at 52 Weeks: Patient Reported Outcomes (PROs)
Query!
Assessment method [18]
0
0
The cough domains of the Cough and Sputum Assessment Questionnaire (CASA- Q) assess the frequency and severity of cough and sputum and their impact on everyday life. It contains 4 domains cough/sputum symptom and impact with each scale ranging from 0 to 100 with lower scores indicating higher symptoms/impact levels (worst outcome).
Means presented are the adjusted means and are based on all analyzed patients in the model (not only patients with a baseline and measurement at week 52).
Query!
Timepoint [18]
0
0
baseline and 52 weeks
Query!
Secondary outcome [19]
0
0
Proportion of Patient's Global Impression of Change (PGI-C) Responders at 52 Weeks: Patient Reported Outcomes (PROs)
Query!
Assessment method [19]
0
0
Patient's Global Impression of Change (PGI-C) responders are defined as 'Very much better'/ 'Much better'/ 'A little better'/ 'No change'.
Query!
Timepoint [19]
0
0
52 weeks
Query!
Secondary outcome [20]
0
0
Change From Baseline in EuroQol 5-Dimensional Quality of Life Questionnaire (EQ-5D) Health State up to 52 Weeks : Patient Reported Outcomes (PROs)
Query!
Assessment method [20]
0
0
The EuroQol 5-dimensional Health State is based on a visual analog scale (EQ-VAS) representing the general patient's health state labelled from 100 (best imaginable health state) to 0 (worst imaginable health state). A higher score indicating a better health state. Change from baseline is calculated as the difference between health state at week 12, 24 and 52 respectively and health state at baseline as measured by the scale.
Query!
Timepoint [20]
0
0
baseline, 12 weeks, 24 weeks and 52 weeks
Query!
Secondary outcome [21]
0
0
Risk of an Acute IPF Exacerbation Over 52 Weeks
Query!
Assessment method [21]
0
0
The incidence rate of exacerbations (calculated as the number of patients with at least 1 acute IPF exacerbation divided by the total number of years at risk in years\*100)
Query!
Timepoint [21]
0
0
52 weeks
Query!
Secondary outcome [22]
0
0
Time to Death Over 52 Weeks
Query!
Assessment method [22]
0
0
Due to rare events, the median of time to event is not calculable, thus the percentages of patients who did or did not experienced death before or at 372 days after randomisation or last contact date (whichever occurs first) are reported.
Failure is the proportion of patients who died over 52 weeks (373 days time-period).
Query!
Timepoint [22]
0
0
52 weeks
Query!
Secondary outcome [23]
0
0
Time to Death Due to Respiratory Cause Over 52 Weeks (Adjudicated)
Query!
Assessment method [23]
0
0
Due to rare events, the median of time to event is not calculable, thus the percentages of participants who did or did not experienced death due to respiratory causes before or at 372 days after randomisation or last contact date (whichever occurs first) are reported.
Failure is the the proportion of patients who died due to respiratory causes over 52 weeks (373 days time-period).
Query!
Timepoint [23]
0
0
52 weeks
Query!
Secondary outcome [24]
0
0
Time to On-treatment Death
Query!
Assessment method [24]
0
0
Due to rare events, the median of time to event is not calculable, thus the percentages of participants who did or did not die before or at last trial medication intake + 28 days were censored at last trial medication intake + 28 days and reported.
Failure is the the proportion of patients who died on-treatment.
Query!
Timepoint [24]
0
0
52 weeks
Query!
Secondary outcome [25]
0
0
Time to Death or Lung Transplant Over 52 Weeks
Query!
Assessment method [25]
0
0
Due to rare events, the median of time to event is not calculable, thus the percentages of participants who did or did not experience event (death or lung transplant) before or at 372 days after randomisation or last contact date (whichever occurs first) are reported. Failure is the proportion of patients who died or had lung transplant over 52 weeks (373 days time-period).
Query!
Timepoint [25]
0
0
52 weeks
Query!
Secondary outcome [26]
0
0
Time to Death or Lung Transplant or Qualifying for Lung Transplant Over 52 Weeks.
Query!
Assessment method [26]
0
0
Due to rare events, the median of time to event is not calculable, thus the percentages of participants who did or did not experienced death or lung transplant or qualifying for lung transplant over 52 weeks are reported. A patient was considered qualifying for lung transplant by the investigator if he or she fulfilled the following criteria:
FVC \<45% predicted or Carbon monoxide diffusion capacity (DL(CO)) \<30% pred or Oxygen saturation on pulse oximetry (SpO2) \<88% at rest, at sea level (to be adapted for other heights).
These criteria were evaluated by investigators judgement. Failure is the proportion of patients who died or had lung transplant or qualified for lung transplant over 52 weeks (373 days time-period).
Query!
Timepoint [26]
0
0
52 weeks
Query!
Secondary outcome [27]
0
0
Change From Baseline in SpO2 (Oxygen Saturation, Expressed in Percent) at Rest up Over 52 Weeks
Query!
Assessment method [27]
0
0
Means presented are the adjusted means. Adjusted mean is based on all analyzed patients in the model (not only patients with a change from baseline to week 52)
Query!
Timepoint [27]
0
0
baseline and 52 weeks
Query!
Secondary outcome [28]
0
0
Change From Baseline in Carbon Monoxide Diffusion Capacity (DLCO) at Rest Over 52 Weeks
Query!
Assessment method [28]
0
0
Means provided are the adjusted means and are based on all analysed patients in the model (not only patients with a change from baseline to week 52).
Query!
Timepoint [28]
0
0
baseline and 52 weeks
Query!
Secondary outcome [29]
0
0
Change From Baseline In Mean NRS Average Pain During The Last Period
Query!
Assessment method [29]
0
0
Participants indicated the level of pain experienced in the last 24 hours on an 11-point Numerical Rating Scale (NRS), where a score of 0 indicated "no pain" and a score of 10 indicated "pain as bad as you can imagine." Change in mean NRS average pain was calculated as: Last Period NRS average pain score - Baseline NRS average pain score.
A negative value indicates an improvement in average pain score from Baseline.
Query!
Timepoint [29]
0
0
Baseline, Last Period (Days 156-183) or last 27 days of treatment
Query!
Secondary outcome [30]
0
0
Change From Baseline In Mean Sleep Disruption NRS During The Last Period
Query!
Assessment method [30]
0
0
Participants indicated the level of sleep disruption experienced in the last 24 hours on an 11-point NRS, where a score of 0 indicated "did not disrupt sleep" and a score of 10 indicated "completely disrupted (unable to sleep at all)." Change in mean sleep disruption NRS was calculated as: Last Period sleep disruption NRS score - Baseline sleep disruption NRS score.
A negative value indicates an improvement in sleep disruption score from Baseline.
Query!
Timepoint [30]
0
0
Baseline, Last Period (Days 156-183) or last 27 days of treatment
Query!
Secondary outcome [31]
0
0
Patient Satisfaction Questionnaire At Last Visit (Up To Day 183)
Query!
Assessment method [31]
0
0
The Patient Satisfaction Questionnaire (PSQ) was used to assess level of satisfaction of the participant with the study drug, with the markers "extremely satisfied, very satisfied, slightly satisfied, neutral, slightly dissatisfied, very dissatisfied, extremely dissatisfied". Last visit refers to the last visit that a participant completed the assessment.
Query!
Timepoint [31]
0
0
Last Visit (up to Day 183)
Query!
Secondary outcome [32]
0
0
Change From Baseline In NRS Constipation At Last Visit (Up To Day 183)
Query!
Assessment method [32]
0
0
Participants indicated level of constipation on an 11-point NRS, where a score of 0 was "no constipation", and 10 was "constipation as bad as you can imagine." Last visit refers to the last visit that a participant completed the assessment.
Change in NRS constipation score was calculated as: Last Visit NRS constipation score - Baseline NRS constipation score.
A negative value indicates improvement in condition from Baseline.
Query!
Timepoint [32]
0
0
Baseline, Last Visit (up to Day 183)
Query!
Eligibility
Key inclusion criteria
Inclusion criteria:
1. Age >= 40 years;
2. IPF diagnosed, according to most recent American Thoracic Society (ATS), European Respiratory Society (ERS), Japanese Respiratory Society (JRS), Latin American Thoracic Association (ALAT) IPF guideline for diagnosis and management, within 5 years;
3. Combination of High Resolution Computerized Tomography (HRCT) pattern, and if available surgical lung biopsy pattern, as assessed by central reviewers, are consistent with diagnosis of IPF
4. Dlco (corrected for Hb): 30%-79% predicted of normal; 5.FVC>= 50% predicted of normal
Query!
Minimum age
40
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
Exclusion criteria:
1. Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT) > 1.5 x Upper Limit of Normal (ULN)
2. Bilirubin > 1.5 x ULN;
3. Relevant airways obstruction (i.e. pre-bronchodilator FEV1/FVC < 0.7);
4. Patient likely to have lung transplantation during study (being on transplantation list is acceptable for participation);
5. Myocardial infarction within 6 months;
6. Unstable angina within 1 month;
7. Bleeding risk (genetic predisposition; fibrinolysis or full-dose therapeutic anticoagulation or high dose antiplatelet therapy; history of hemorrhagic CNS event within 12 months; haemoptysis or haematuria or active gastro-intestinal bleeding or ulcers or major injury or surgery within 3 months);
8. Thrombotic risk (inherited predisposition; history of thrombotic event (including stroke and transient ischemic attacks) within 12 months;
9. International normalised ratio (INR) > 2, prolongation of prothrombin time (PT) and partial thromboplastin time (PTT) by > 50% of institutional ULN);
10. N-ACetyl Cystein, prednisone > 15mg/day or equivalent received within 2 weeks of visit 1;
11. Pirfenidone, azathioprine, cyclophosphamide, cyclosporine A received within 8 weeks of visit 1;
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/05/2011
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
1/10/2013
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
551
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Arizona
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
California
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Connecticut
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Florida
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Georgia
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Illinois
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Kansas
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Kentucky
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Minnesota
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Missouri
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
New Hampshire
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
New York
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
North Carolina
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Ohio
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Oregon
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
Pennsylvania
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
South Carolina
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
Texas
Query!
Country [19]
0
0
United States of America
Query!
State/province [19]
0
0
Utah
Query!
Country [20]
0
0
United States of America
Query!
State/province [20]
0
0
Vermont
Query!
Country [21]
0
0
United States of America
Query!
State/province [21]
0
0
Wisconsin
Query!
Country [22]
0
0
Canada
Query!
State/province [22]
0
0
Alberta
Query!
Country [23]
0
0
Canada
Query!
State/province [23]
0
0
Nova Scotia
Query!
Country [24]
0
0
Canada
Query!
State/province [24]
0
0
Ontario
Query!
Country [25]
0
0
Chile
Query!
State/province [25]
0
0
Santiago de Chile
Query!
Country [26]
0
0
China
Query!
State/province [26]
0
0
Beijing
Query!
Country [27]
0
0
China
Query!
State/province [27]
0
0
Shanghai
Query!
Country [28]
0
0
China
Query!
State/province [28]
0
0
Shenyang
Query!
Country [29]
0
0
China
Query!
State/province [29]
0
0
Yinchuan
Query!
Country [30]
0
0
Finland
Query!
State/province [30]
0
0
Helsinki
Query!
Country [31]
0
0
France
Query!
State/province [31]
0
0
Dijon Cedex
Query!
Country [32]
0
0
France
Query!
State/province [32]
0
0
Lille Cedex
Query!
Country [33]
0
0
France
Query!
State/province [33]
0
0
Lyon Cedex
Query!
Country [34]
0
0
France
Query!
State/province [34]
0
0
Marseille
Query!
Country [35]
0
0
France
Query!
State/province [35]
0
0
Montpellier cedex 5
Query!
Country [36]
0
0
France
Query!
State/province [36]
0
0
Toulouse cedex 9
Query!
Country [37]
0
0
Germany
Query!
State/province [37]
0
0
Bad Berka
Query!
Country [38]
0
0
Germany
Query!
State/province [38]
0
0
Berlin-Buch
Query!
Country [39]
0
0
Germany
Query!
State/province [39]
0
0
Berlin
Query!
Country [40]
0
0
Germany
Query!
State/province [40]
0
0
Coswig
Query!
Country [41]
0
0
Germany
Query!
State/province [41]
0
0
Essen
Query!
Country [42]
0
0
Germany
Query!
State/province [42]
0
0
Greifswald
Query!
Country [43]
0
0
Germany
Query!
State/province [43]
0
0
Immenhausen
Query!
Country [44]
0
0
Germany
Query!
State/province [44]
0
0
Köln
Query!
Country [45]
0
0
Germany
Query!
State/province [45]
0
0
München
Query!
Country [46]
0
0
Germany
Query!
State/province [46]
0
0
Münster
Query!
Country [47]
0
0
Greece
Query!
State/province [47]
0
0
Athens
Query!
Country [48]
0
0
Greece
Query!
State/province [48]
0
0
Heraklion
Query!
Country [49]
0
0
Greece
Query!
State/province [49]
0
0
Larisa
Query!
Country [50]
0
0
Greece
Query!
State/province [50]
0
0
Maroussi, Athens
Query!
Country [51]
0
0
Greece
Query!
State/province [51]
0
0
Nikaia
Query!
Country [52]
0
0
India
Query!
State/province [52]
0
0
Ahmedabad
Query!
Country [53]
0
0
India
Query!
State/province [53]
0
0
Banglore
Query!
Country [54]
0
0
India
Query!
State/province [54]
0
0
Jaipur
Query!
Country [55]
0
0
India
Query!
State/province [55]
0
0
Pune
Query!
Country [56]
0
0
Japan
Query!
State/province [56]
0
0
Himeji, Hyogo
Query!
Country [57]
0
0
Japan
Query!
State/province [57]
0
0
Kawasaki, Kanagawa
Query!
Country [58]
0
0
Japan
Query!
State/province [58]
0
0
Kobe, Hyogo
Query!
Country [59]
0
0
Japan
Query!
State/province [59]
0
0
Minato-ku, Tokyo
Query!
Country [60]
0
0
Japan
Query!
State/province [60]
0
0
Nagoya, Aichi
Query!
Country [61]
0
0
Japan
Query!
State/province [61]
0
0
Ogaki, Gifu
Query!
Country [62]
0
0
Japan
Query!
State/province [62]
0
0
Osaka-Sayama, Osaka
Query!
Country [63]
0
0
Japan
Query!
State/province [63]
0
0
Sakai, Osaka
Query!
Country [64]
0
0
Japan
Query!
State/province [64]
0
0
Seto, Aichi
Query!
Country [65]
0
0
Japan
Query!
State/province [65]
0
0
Shinjuku-ku, Tokyo
Query!
Country [66]
0
0
Japan
Query!
State/province [66]
0
0
Tenri, Nara
Query!
Country [67]
0
0
Japan
Query!
State/province [67]
0
0
Tokushima, Tokushima
Query!
Country [68]
0
0
Japan
Query!
State/province [68]
0
0
Yonago, Tottori
Query!
Country [69]
0
0
Korea, Republic of
Query!
State/province [69]
0
0
Bucheon
Query!
Country [70]
0
0
Korea, Republic of
Query!
State/province [70]
0
0
Incheon
Query!
Country [71]
0
0
Korea, Republic of
Query!
State/province [71]
0
0
Seoul
Query!
Country [72]
0
0
Mexico
Query!
State/province [72]
0
0
Mexico DF
Query!
Country [73]
0
0
Netherlands
Query!
State/province [73]
0
0
Amsterdam
Query!
Country [74]
0
0
Netherlands
Query!
State/province [74]
0
0
Nieuwegein
Query!
Country [75]
0
0
Netherlands
Query!
State/province [75]
0
0
Rotterdam
Query!
Country [76]
0
0
Portugal
Query!
State/province [76]
0
0
Amadora
Query!
Country [77]
0
0
Portugal
Query!
State/province [77]
0
0
Coimbra
Query!
Country [78]
0
0
Portugal
Query!
State/province [78]
0
0
Lisboa
Query!
Country [79]
0
0
Portugal
Query!
State/province [79]
0
0
Porto
Query!
Country [80]
0
0
Portugal
Query!
State/province [80]
0
0
Vila Nova de Gaia
Query!
Country [81]
0
0
Russian Federation
Query!
State/province [81]
0
0
Kazan
Query!
Country [82]
0
0
Russian Federation
Query!
State/province [82]
0
0
St. Petersburg
Query!
Country [83]
0
0
Spain
Query!
State/province [83]
0
0
Barcelona
Query!
Country [84]
0
0
Spain
Query!
State/province [84]
0
0
Hospitalet de Llobregat
Query!
Country [85]
0
0
Spain
Query!
State/province [85]
0
0
Madrid
Query!
Country [86]
0
0
Spain
Query!
State/province [86]
0
0
Sevilla
Query!
Country [87]
0
0
Turkey
Query!
State/province [87]
0
0
Ankara
Query!
Country [88]
0
0
Turkey
Query!
State/province [88]
0
0
Istanbul
Query!
Country [89]
0
0
Turkey
Query!
State/province [89]
0
0
Izmir
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
Boehringer Ingelheim
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
Idiopathic Pulmonary Fibrosis (IPF) is a chronic disease of unknown cause that results in scarring of the lung and there is a high unmet medical need for effective treatment to halt lung function decline, delay or avoid exacerbation (flare-ups), and ultimately to reduce the death rate. In a large Phase 2 trial (1199.30) (NCT00514683), investigating the effects of 52 weeks of treatment with BIBF 1120 in patients with IPF, a positive effect was seen on lung function of patients treated with high dose of BIBF 1120 compared to placebo. Hence it is the purpose of this trial to investigate and confirm the efficacy and safety of BIBF 1120 at a high dose in treating patients with IPF, compared with placebo. The trial will be conducted as a prospective, randomised design with the aim to collect safety and efficacy data. Respiratory function is globally accepted for assessment of treatment effects in IPF patients. The chosen endpoint (Forced Vital Capacity (FVC) decline) is easy to obtain and is part of the usual examinations done in IPF patients.
Query!
Trial website
https://clinicaltrials.gov/study/NCT01335477
Query!
Trial related presentations / publications
Glaspole I, Bonella F, Bargagli E, Glassberg MK, Caro F, Stansen W, Quaresma M, Orsatti L, Bendstrup E. Efficacy and safety of nintedanib in patients with idiopathic pulmonary fibrosis who are elderly or have comorbidities. Respir Res. 2021 Apr 26;22(1):125. doi: 10.1186/s12931-021-01695-y. Jouneau S, Crestani B, Thibault R, Lederlin M, Vernhet L, Valenzuela C, Wijsenbeek M, Kreuter M, Stansen W, Quaresma M, Cottin V. Analysis of body mass index, weight loss and progression of idiopathic pulmonary fibrosis. Respir Res. 2020 Nov 25;21(1):312. doi: 10.1186/s12931-020-01528-4. Brown KK, Martinez FJ, Walsh SLF, Thannickal VJ, Prasse A, Schlenker-Herceg R, Goeldner RG, Clerisme-Beaty E, Tetzlaff K, Cottin V, Wells AU. The natural history of progressive fibrosing interstitial lung diseases. Eur Respir J. 2020 Jun 25;55(6):2000085. doi: 10.1183/13993003.00085-2020. Print 2020 Jun. Richeldi L, Kolb M, Jouneau S, Wuyts WA, Schinzel B, Stowasser S, Quaresma M, Raghu G. Efficacy and safety of nintedanib in patients with advanced idiopathic pulmonary fibrosis. BMC Pulm Med. 2020 Jan 8;20(1):3. doi: 10.1186/s12890-019-1030-4. Kreuter M, Koegler H, Trampisch M, Geier S, Richeldi L. Differing severities of acute exacerbations of idiopathic pulmonary fibrosis (IPF): insights from the INPULSIS(R) trials. Respir Res. 2019 Apr 11;20(1):71. doi: 10.1186/s12931-019-1037-7. Xu Z, Li H, Wen F, Bai C, Chen P, Fan F, Hu N, Stowasser S, Kang J. Subgroup Analysis for Chinese Patients Included in the INPULSIS(R) Trials on Nintedanib in Idiopathic Pulmonary Fibrosis. Adv Ther. 2019 Mar;36(3):621-631. doi: 10.1007/s12325-019-0887-1. Epub 2019 Feb 7. Costabel U, Behr J, Crestani B, Stansen W, Schlenker-Herceg R, Stowasser S, Raghu G. Anti-acid therapy in idiopathic pulmonary fibrosis: insights from the INPULSIS(R) trials. Respir Res. 2018 Sep 3;19(1):167. doi: 10.1186/s12931-018-0866-0. Collard HR, Richeldi L, Kim DS, Taniguchi H, Tschoepe I, Luisetti M, Roman J, Tino G, Schlenker-Herceg R, Hallmann C, du Bois RM. Acute exacerbations in the INPULSIS trials of nintedanib in idiopathic pulmonary fibrosis. Eur Respir J. 2017 May 19;49(5):1601339. doi: 10.1183/13993003.01339-2016. Print 2017 May. Paterniti MO, Bi Y, Rekic D, Wang Y, Karimi-Shah BA, Chowdhury BA. Acute Exacerbation and Decline in Forced Vital Capacity Are Associated with Increased Mortality in Idiopathic Pulmonary Fibrosis. Ann Am Thorac Soc. 2017 Sep;14(9):1395-1402. doi: 10.1513/AnnalsATS.201606-458OC. Rinciog C, Watkins M, Chang S, Maher TM, LeReun C, Esser D, Diamantopoulos A. A Cost-Effectiveness Analysis of Nintedanib in Idiopathic Pulmonary Fibrosis in the UK. Pharmacoeconomics. 2017 Apr;35(4):479-491. doi: 10.1007/s40273-016-0480-2. Kolb M, Richeldi L, Behr J, Maher TM, Tang W, Stowasser S, Hallmann C, du Bois RM. Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume. Thorax. 2017 Apr;72(4):340-346. doi: 10.1136/thoraxjnl-2016-208710. Epub 2016 Sep 26. Corte T, Bonella F, Crestani B, Demedts MG, Richeldi L, Coeck C, Pelling K, Quaresma M, Lasky JA. Safety, tolerability and appropriate use of nintedanib in idiopathic pulmonary fibrosis. Respir Res. 2015 Sep 24;16:116. doi: 10.1186/s12931-015-0276-5. Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, Cottin V, Flaherty KR, Hansell DM, Inoue Y, Kim DS, Kolb M, Nicholson AG, Noble PW, Selman M, Taniguchi H, Brun M, Le Maulf F, Girard M, Stowasser S, Schlenker-Herceg R, Disse B, Collard HR; INPULSIS Trial Investigators. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014 May 29;370(22):2071-82. doi: 10.1056/NEJMoa1402584. Epub 2014 May 18. Erratum In: N Engl J Med. 2015 Aug 20;373(8):782. doi: 10.1056/NEJMx150012. Richeldi L, Cottin V, Flaherty KR, Kolb M, Inoue Y, Raghu G, Taniguchi H, Hansell DM, Nicholson AG, Le Maulf F, Stowasser S, Collard HR. Design of the INPULSIS trials: two phase 3 trials of nintedanib in patients with idiopathic pulmonary fibrosis. Respir Med. 2014 Jul;108(7):1023-30. doi: 10.1016/j.rmed.2014.04.011. Epub 2014 Apr 29.
Query!
Public notes
This record is viewable in the ANZCTR as it had previously listed Australia and/or New Zealand as a recruitment site, however these sites have since been removed
Query!
Contacts
Principal investigator
Name
0
0
Boehringer Ingelheim
Query!
Address
0
0
Boehringer Ingelheim
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results are available at
https://clinicaltrials.gov/study/NCT01335477
Download to PDF